{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T08:11:50Z","timestamp":1790583110133,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:00:00Z","timestamp":1696550400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ejmech.2023.115837","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T11:52:54Z","timestamp":1696593174000},"page":"115837","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["PITB: A high affinity transthyretin aggregation inhibitor with optimal pharmacokinetic properties"],"prefix":"10.1016","volume":"261","author":[{"given":"Francisca","family":"Pinheiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalia","family":"Varej\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e0","family":"S\u00e1nchez-Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipa","family":"Bezerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e1n","family":"Vel\u00e1zquez-Campoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e9lix","family":"Busqu\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Ros\u00e1rio","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Alib\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Reverter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irantzu","family":"Pallar\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9652-6351","authenticated-orcid":false,"given":"Salvador","family":"Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115837_bib1","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev.biochem.75.101304.123901","article-title":"Protein misfolding, functional amyloid, and human disease","volume":"75","author":"Chiti","year":"2006","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejmech.2023.115837_bib2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40120-020-00210-7","article-title":"Transthyretin amyloidosis: update on the clinical spectrum, pathogenesis, and disease-modifying therapies","volume":"9","author":"Koike","year":"2020","journal-title":"Neurol Ther"},{"key":"10.1016\/j.ejmech.2023.115837_bib3","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1210\/jcem-37-3-415","article-title":"Transport of thyroid hormones in serum and cerebrospinal fluid","volume":"37","author":"Hagen","year":"1973","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejmech.2023.115837_bib4","first-page":"R338","article-title":"Thyroxine transport from blood to brain via transthyretin synthesis in choroid plexus","volume":"258","author":"Schreiber","year":"1990","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.ejmech.2023.115837_bib5","doi-asserted-by":"crossref","first-page":"6105","DOI":"10.1007\/s00018-021-03899-3","article-title":"The role of transthyretin in cell biology: impact on human pathophysiology","volume":"78","author":"Magalhaes","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2023.115837_bib6","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/jnnp-2021-327909","article-title":"Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis","volume":"93","author":"Carroll","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ejmech.2023.115837_bib7","doi-asserted-by":"crossref","first-page":"E2403","DOI":"10.1002\/humu.22619","article-title":"Online registry for mutations in hereditary amyloidosis including nomenclature recommendations","volume":"35","author":"Rowczenio","year":"2014","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ejmech.2023.115837_bib8","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/brain\/75.3.408","article-title":"A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves","volume":"75","author":"Andrade","year":"1952","journal-title":"Brain"},{"key":"10.1016\/j.ejmech.2023.115837_bib9","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejmech.2023.115837_bib10","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/brain\/103.3.473","article-title":"Familial oculoleptomeningeal amyloidosis","volume":"103","author":"Goren","year":"1980","journal-title":"Brain"},{"key":"10.1016\/j.ejmech.2023.115837_bib11","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1073\/pnas.87.7.2843","article-title":"Fibril in senile systemic amyloidosis is derived from normal transthyretin","volume":"87","author":"Westermark","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2023.115837_bib12","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1080\/07853890701842988","article-title":"Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study","volume":"40","author":"Tanskanen","year":"2008","journal-title":"Ann. Med."},{"key":"10.1016\/j.ejmech.2023.115837_bib13","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/0002-9343(83)90443-6","article-title":"Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation","volume":"75","author":"Cornwell","year":"1983","journal-title":"Am. J. Med."},{"issue":"Suppl 4","key":"10.1016\/j.ejmech.2023.115837_bib14","doi-asserted-by":"crossref","first-page":"16427","DOI":"10.1073\/pnas.202495199","article-title":"Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity","volume":"99","author":"Hammarstrom","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2023.115837_bib15","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1021\/bi800636q","article-title":"Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis","volume":"47","author":"Hurshman Babbes","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2023.115837_bib16","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1126\/science.1079589","article-title":"Prevention of transthyretin amyloid disease by changing protein misfolding energetics","volume":"299","author":"Hammarstrom","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2023.115837_bib17","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1021\/ar020073i","article-title":"Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses","volume":"38","author":"Johnson","year":"2005","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ejmech.2023.115837_bib18","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1073\/pnas.1121005109","article-title":"Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade","volume":"109","author":"Bulawa","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2023.115837_bib19","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/13506129.2017.1357545","article-title":"Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years","volume":"24","author":"Barroso","year":"2017","journal-title":"Amyloid"},{"key":"10.1016\/j.ejmech.2023.115837_bib20","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.115837_bib21","first-page":"4","article-title":"Predictive model of response to tafamidis in hereditary ATTR polyneuropathy","author":"Monteiro","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.ejmech.2023.115837_bib22","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ejmech.2023.115837_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10787","article-title":"Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity","volume":"7","author":"Sant'Anna","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115837_bib24","doi-asserted-by":"crossref","first-page":"P9","DOI":"10.1186\/1750-1172-10-S1-P9","article-title":"SOM0226, a repositioned compound for the treatment of TTR amyloidosis","volume":"10","author":"Reig","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ejmech.2023.115837_bib25","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/13506129.2019.1597702","article-title":"Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study(and)","volume":"26","author":"Gamez","year":"2019","journal-title":"Amyloid"},{"key":"10.1016\/j.ejmech.2023.115837_bib26","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/febs.15339","article-title":"Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis","volume":"288","author":"Pinheiro","year":"2021","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2023.115837_bib27","doi-asserted-by":"crossref","first-page":"14673","DOI":"10.1021\/acs.jmedchem.2c01195","article-title":"Development of a highly potent transthyretin amyloidogenesis inhibitor: design, synthesis, and evaluation","volume":"65","author":"Pinheiro","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115837_bib28","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1046\/j.1365-2125.1999.00036.x","article-title":"Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase","volume":"48","author":"Jorga","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115837_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104144","article-title":"Interactions of tolcapone analogues as stabilizers of the amyloidogenic protein transthyretin","volume":"103","author":"Loconte","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.115837_bib30","doi-asserted-by":"crossref","first-page":"11453","DOI":"10.1021\/bi010673+","article-title":"Anion shielding of electrostatic repulsions in transthyretin modulates stability and amyloidosis: insight into the chaotrope unfolding dichotomy","volume":"40","author":"Hammarstrom","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2023.115837_bib31","doi-asserted-by":"crossref","first-page":"14943","DOI":"10.1073\/pnas.261419998","article-title":"The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis","volume":"98","author":"Jiang","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2023.115837_bib32","doi-asserted-by":"crossref","first-page":"28932","DOI":"10.1074\/jbc.M115.659912","article-title":"Uncovering the mechanism of aggregation of human transthyretin","volume":"290","author":"Saelices","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115837_bib33","doi-asserted-by":"crossref","first-page":"9992","DOI":"10.1073\/pnas.1300761110","article-title":"AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin","volume":"110","author":"Penchala","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2023.115837_bib34","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1021\/bi00673a014","article-title":"Negative cooperativity in the binding of thyroxine to human serum prealbumin. Preparation of tritium-labeled 8-anilino-1-naphthalenesulfonic acid","volume":"14","author":"Ferguson","year":"1975","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2023.115837_bib35","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ymeth.2014.09.010","article-title":"A unified framework based on the binding polynomial for characterizing biological systems by isothermal titration calorimetry","volume":"76","author":"Vega","year":"2015","journal-title":"Methods"},{"key":"10.1016\/j.ejmech.2023.115837_bib36","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0076-6879(08)04205-5","article-title":"Isothermal titration calorimetry: general formalism using binding polynomials","volume":"455","author":"Freire","year":"2009","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.ejmech.2023.115837_bib37","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/acn3.50887","article-title":"Biophysical characterization and modulation of transthyretin Ala97Ser","volume":"6","author":"Liu","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.ejmech.2023.115837_bib38","doi-asserted-by":"crossref","first-page":"53483","DOI":"10.1074\/jbc.M408053200","article-title":"The crystal structure of transthyretin in complex with diethylstilbestrol: a promising template for the design of amyloid inhibitors","volume":"279","author":"Morais-de-Sa","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115837_bib39","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1006\/jmbi.2000.4415","article-title":"Transthyretin stability as a key factor in amyloidogenesis: X-ray analysis at atomic resolution","volume":"306","author":"Sebastiao","year":"2001","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2023.115837_bib40","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1042\/BJ20040011","article-title":"Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative","volume":"381","author":"Almeida","year":"2004","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2023.115837_bib41","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1016\/j.febslet.2009.10.062","article-title":"Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity","volume":"583","author":"Ferreira","year":"2009","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejmech.2023.115837_bib42","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.tiv.2005.01.003","article-title":"Cytotoxic effects of 100 reference compounds on Hep G2 and HeLa cells and of 60 compounds on ECC-1 and CHO cells. I mechanistic assays on ROS, glutathione depletion and calcein uptake","volume":"19","author":"Schoonen","year":"2005","journal-title":"Toxicol. Vitro"},{"key":"10.1016\/j.ejmech.2023.115837_bib43","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/j.2042-7158.1997.tb06055.x","article-title":"Screening of hepatoprotective plant components using a HepG2 cell cytotoxicity assay","volume":"49","author":"Thabrew","year":"1997","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115837_bib44","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0300-483X(80)90010-4","article-title":"Toxicity to HeLa cell of 205 drugs as determined by the metabolic inhibition test supplemented by microscopy","volume":"17","author":"Ekwall","year":"1980","journal-title":"Toxicology"},{"key":"10.1016\/j.ejmech.2023.115837_bib45","doi-asserted-by":"crossref","DOI":"10.5812\/hepatmon.11447","article-title":"In vitro analysis of CsA-induced hepatotoxicity in HepG2 cell line: oxidative stress and alpha2 and beta1 integrin subunits expression","volume":"13","author":"Mostafavi-Pour","year":"2013","journal-title":"Hepat. Mon."},{"key":"10.1016\/j.ejmech.2023.115837_bib46","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1177\/0960327112459530","article-title":"Antioxidative and cytoprotective effects of andrographolide against CCl4-induced hepatotoxicity in HepG2 cells","volume":"32","author":"Krithika","year":"2013","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.ejmech.2023.115837_bib47","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMra021844","article-title":"Drug-induced hepatotoxicity","volume":"349","author":"Lee","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.115837_bib48","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1001\/archneur.57.2.263","article-title":"Tolcapone and hepatotoxic effects. Tasmar advisory panel","volume":"57","author":"Olanow","year":"2000","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ejmech.2023.115837_bib49","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1146\/annurev.pharmtox.39.1.19","article-title":"Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase","volume":"39","author":"Weinshilboum","year":"1999","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejmech.2023.115837_bib50","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1081\/DMR-120001392","article-title":"Summary of information on human CYP enzymes: human P450 metabolism data","volume":"34","author":"Rendic","year":"2002","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.ejmech.2023.115837_bib51","doi-asserted-by":"crossref","first-page":"11442","DOI":"10.1021\/bi011194d","article-title":"An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured","volume":"40","author":"Jiang","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2023.115837_bib52","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1107\/S160057751400825X","article-title":"Developments in optics and performance at BL13-XALOC, the macromolecular crystallography beamline at the ALBA synchrotron","volume":"21","author":"Juanhuix","year":"2014","journal-title":"J. Synchrotron Radiat."},{"key":"10.1016\/j.ejmech.2023.115837_bib53","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1107\/S0907444909047374","article-title":"Integration, scaling, space-group assignment and post-refinement","volume":"66","author":"Kabsch","year":"2010","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.ejmech.2023.115837_bib54","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1107\/S0907444910045749","article-title":"Overview of the CCP4 suite and current developments","volume":"67","author":"Winn","year":"2011","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.ejmech.2023.115837_bib55","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1107\/S0907444909052925","article-title":"PHENIX: a comprehensive Python-based system for macromolecular structure solution","volume":"66","author":"Adams","year":"2010","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.ejmech.2023.115837_bib56","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of Coot","volume":"66","author":"Emsley","year":"2010","journal-title":"Acta Crystallogr D Biol Crystallogr"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423008048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423008048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:02:49Z","timestamp":1759330969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423008048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":56,"alternative-id":["S0223523423008048"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115837","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PITB: A high affinity transthyretin aggregation inhibitor with optimal pharmacokinetic properties","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115837","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115837"}}